19 noviembre 2014

CIRCULATION. Interventional Cardiology. Long-Term Efficacy and Safety of Biodegradable-Polymer Biolimus-Eluting Stents. Main Results of the Basel Stent Kosten-Effektivitäts Trial–PROspective Validation Examination II (BASKET-PROVE II), A Randomized, Controlled Noninferiority 2-Year Outcome Trial

Christoph Kaiser, MD*; Soeren Galatius, MD*; Raban Jeger, MD; Nicole Gilgen, MD; Jan Skov Jensen, MD; Christoph Naber, MD; Hannes Alber, MD; Maria Wanitschek, MD; Franz Eberli, MD; David J. Kurz, MD; Giovanni Pedrazzini, MD; Tiziano Moccetti, MD; Hans Rickli, MD; Daniel Weilenmann, MD; André Vuillomenet, MD; Martin Steiner, MD; Stefanie Von Felten, PhD; Deborah R. Vogt, PhD; Kim Wadt Hansen, MD; Peter Rickenbacher, MD; David Conen, MD; Christian Müller, MD; Peter Buser, MD; Andreas Hoffmann, MD; Matthias Pfisterer, MD; for the BASKET-PROVE II Study group**

Background: Biodegradable-polymer drug-eluting stents (BP-DES) were developed to be as effective as second-generation durable-polymer drug-eluting stents (DP-DES) and as safe >1 year as bare-metal stents (BMS). Thus, very late stent thrombosis (VLST) attributable to durable polymers should no longer appear.

16 noviembre 2014

CIRCULATION. Interventional Cardiology. Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Liberté Paclitaxel-Eluting Coronary Stent Placement

Kirk N. Garratt, MD, MSc; W. Douglas Weaver, MD; Ronald G. Jenkins, MD; Thomas K. Pow, MD; Laura Mauri, MD, MSc; Dean J. Kereiakes, MD; Kenneth J. Winters, MD; Thomas Christen, MD, PhD; Dominic J. Allocco, MD, MSc; David P. Lee, MD

Background: The TAXUS Liberté Post Approval Study (TL-PAS) contributed patients treated with TAXUS Liberté paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 30 months thienopyridine plus aspirin therapy after drug-eluting stents.

19 noviembre 2013

CIRCULATION. Coronary Heart Disease. Outcome Impact of Coronary Revascularization Strategy Reclassification With Fractional Flow Reserve at Time of Diagnostic Angiography

Eric Van Belle, MD, PhD; Gilles Rioufol, MD, PhD; Christophe Pouillot, MD; Thomas Cuisset, MD, PhD; Karim Bougrini, MD; Emmanuel Teiger, MD, PhD; Stéphane Champagne, MD; Loic Belle, MD; Didier Barreau, MD; Michel Hanssen, MD; Cyril Besnard, MD; Raphael Dauphin, MD; Jean Dallongeville, MD, PhD; Yassine El Hahi, MSc; Georgios Sideris, MD; Christophe Bretelle, MD; Nicolas Lhoest, MD; Pierre Barnay, MD; Laurent Leborgne, MD, PhD; Patrick Dupouy, MD; for the Investigators of the Registre Français de la FFR – R3F

Background: There is no large report of the impact of fractional flow reserve (FFR) on the reclassification of the coronary revascularization strategy on individual patients referred for diagnostic angiography.

27 septiembre 2013

CIRCULATION. Interventional Cardiology. Inaccuracy of Estimated Resting Oxygen Uptake in the Clinical Setting

Nikhil Narang, MD; Jennifer T. Thibodeau, MD, MSc; Benjamin D. Levine, MD; M. Odette Gore, MD; Colby R. Ayers, MS; Richard A. Lange, MD, MBA; Joaquin E. Cigarroa, MD; Aslan T. Turer, MD, MHS; James A. de Lemos, MD; Darren K. McGuire, MD, MHSc

Background: The Fick principle (cardiac output = oxygen uptake (GraphicO2)/systemic arterio-venous oxygen difference) is used to determine cardiac output in numerous clinical situations. However, estimated rather than measured GraphicO2 is commonly used because of complexities of the measurement, though the accuracy of estimation remains uncertain in contemporary clinical practice.

25 octubre 2013

CIRCULATION. Interventional Cardiology. Pathology of Second-Generation Everolimus-Eluting Stents Versus First-Generation Sirolimus- and Paclitaxel-Eluting Stents in Humans

Fumiyuki Otsuka, MD, PhD; Marc Vorpahl, MD; Masataka Nakano, MD; Jason Foerst, MD; John B. Newell, AB; Kenichi Sakakura, MD; Robert Kutys, MS; Elena Ladich, MD; Aloke V. Finn, MD; Frank D. Kolodgie, PhD; Renu Virmani, MD

Background: Clinical trials have demonstrated that the second-generation cobalt-chromium everolimus-eluting stent (CoCr-EES) is superior to the first-generation paclitaxel-eluting stent (PES) and is noninferior or superior to the sirolimus-eluting stent (SES) in terms of safety and efficacy. It remains unclear whether vascular responses to CoCr-EES are different from those to SES and PES because the pathology of CoCr-EES has not been described in humans.

29 octubre 2013

CIRCULATION. Coronary Heart Disease. Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization

Lars Wallentin, MD, PhD; Daniel Lindholm, MD; Agneta Siegbahn, MD, PhD; Lisa Wernroth, MSc; Richard C. Becker, MD; Christopher P. Cannon, MD; Jan H. Cornel, MD, PhD; Anders Himmelmann, MD, PhD; Evangelos Giannitsis, MD; Robert A. Harrington, MD; Claes Held, MD, PhD; Steen Husted, MD, DSc; Hugo A. Katus, MD; Kenneth W. Mahaffey, MD; Ph. Gabriel Steg, MD; Robert F. Storey, MD, DM; Stefan K. James, MD, PhD; for the PLATO study group

Background: Risk stratification and the use of specific biomarkers have been proposed for tailoring treatment in patients with non–ST-elevation acute coronary syndrome (NSTE-ACS). We investigated the prognostic importance of high-sensitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) in relation to randomized treatment (ticagrelor versus clopidogrel) and management strategy (with or without revascularization) in the NSTE-ACS subgroup of the Platelet Inhibition and Patient Outcomes (PLATO) trial.

04 octubre 2013

CIRCULATION. Coronary Heart Disease. Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

Cheol Whan Lee, MD*; Jung-Min Ahn, MD*; Duk-Woo Park, MD; Soo-Jin Kang, MD; Seung-Whan Lee, MD; Young-Hak Kim, MD; Seong-Wook Park, MD; Seungbong Han, PhD; Sang-Gon Lee, MD; In-Whan Seong, MD; Seung-Woon Rha, MD; Myung-Ho Jeong, MD; Do-Sun Lim, MD; Jung-Han Yoon, MD; Seung-Ho Hur, MD; Yun-Seok Choi, MD; Joo-Young Yang, MD; Nae-Hee Lee, MD; Hyun-Sook Kim, MD; Bong-Ki Lee, MD; Kee-Sik Kim, MD; Seung-Uk Lee, MD; Jei-Keon Chae, MD; Sang-Sig Cheong, MD; Il-woo Suh, MD; Hun-Sik Park, MD; Deuk-Young Nah, MD; Doo-Soo Jeon, MD; Ki-Bae Seung, MD; Keun Lee, MD; Jae-Sik Jang, MD; Seung-Jung Park, MD, PhD

Background: The risks and benefits of long-term dual antiplatelet therapy remain unclear.

26 noviembre 2013

CIRCULATION. Imaging. Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents. The Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) Study

Bernhard Witzenbichler, MD*; Akiko Maehara, MD*; Giora Weisz, MD; Franz-Josef Neumann, MD; Michael J. Rinaldi, MD; D. Christopher Metzger, MD; Timothy D. Henry, MD; David A. Cox, MD; Peter L. Duffy, MD, MMM; Bruce R. Brodie, MD; Thomas D. Stuckey, MD; Ernest L. Mazzaferri Jr, MD; Ke Xu, PhD; Helen Parise, ScD; Roxana Mehran, MD; Gary S. Mintz, MD; Gregg W. Stone, MD

Background: Prior small to modest-sized studies suggest a benefit of intravascular ultrasound (IVUS) guidance in noncomplex lesions. Whether IVUS guidance is associated with improved clinical outcomes after drug-eluting stent (DES) implantation in an unrestricted patient population is unknown.

18 noviembre 2013

CIRCULATION. Interventional Cardiology. Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism

Nils Kucher, MD; Peter Boekstegers, MD; Oliver J. Müller, MD; Christian Kupatt, MD; Jan Beyer-Westendorf, MD; Thomas Heitzer, MD; Ulrich Tebbe, MD; Jan Horstkotte, MD; Ralf Müller, MD; Erwin Blessing, MD; Martin Greif, MD; Philipp Lange, MD; Ralf-Thorsten Hoffmann, MD; Sebastian Werth, MD; Achim Barmeyer, MD; Dirk Härtel, MD; Henriette Grünwald, MD; Klaus Empen, MD; Iris Baumgartner, MD

Background: In patients with acute pulmonary embolism, systemic thrombolysis improves right ventricular (RV) dilatation, is associated with major bleeding, and is withheld in many patients at risk. This multicenter randomized, controlled trial investigated whether ultrasound-assisted catheter-directed thrombolysis (USAT) is superior to anticoagulation alone in the reversal of RV dilatation in intermediate-risk patients.

16 diciembre 2013

CIRCULATION. Vascular Medicine. Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis

Sam Schulman, MD, PhD; Ajay K. Kakkar, MB, BS, PhD; Samuel Z. Goldhaber, MD; Sebastian Schellong, MD; Henry Eriksson, MD, PhD; Patrick Mismetti, MD; Anita Vedel Christiansen, MSc Pharm; Jeffrey Friedman, MD; Florence Le Maulf, BSc (Hons), MSc; Nuala Peter, BSc (Hons), MSc; Clive Kearon, MB, PhD; for the RE-COVER II Trial Investigators*

Background: Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings.

22 noviembre 2013

CIRCULATION. Epidemiology and Prevention. Impact of Incident Venous Thromboembolism on Risk of Arterial Thrombotic Diseases

Caroline Lind, BSc; Linda E. Flinterman, PhD; Kristin F. Enga, MD, PhD; Marianne T. Severinsen, MD, PhD; Søren R. Kristensen, MD, PhD; Sigrid K. Brækkan, PhD; Ellisiv B. Mathiesen, MD, PhD; Inger Njølstad, MD, PhD; Suzanne C. Cannegieter, MD, PhD; Kim Overvad, MD, PhD; John-Bjarne Hansen, MD, PhD

Background: Growing evidence supports an association between venous thromboembolism (VTE) and arterial thrombotic diseases (ie, myocardial infarction and ischemic stroke). We aimed to study the association between VTE and future arterial events and to determine the population attributable risk of arterial events by VTE in a large prospective cohort recruited from the general population.

01 diciembre 2014

CIRCULATION. Images in Cardiovascular Medicine. Neoatherosclerosis After Paclitaxel-Coated Balloon Angioplasty for In-Stent Restenosis

Fernando Alfonso, MD; Pilar Jimenez-Quevedo, MD; Nieves Gonzalo, MD; Miguel Medina, MD; Camino Bañuelos, MD

Introduction: In-stent neoatherosclerosis (NA) has been reported after drug-eluting stent (DES) and bare-metal stent implantation.1 NA is not only more frequent but also occurs earlier in patients undergoing DES implantation compared with those treated with bare-metal stents.1 This phenomenon has major potential implications because complicated NA (mainly from rupture of a thin-cap fibroatheroma) may result in very late stent thrombosis.2 Although NA can be visualized using intravascular ultrasound (IVUS), optical coherence tomography (OCT), because of its unique resolution (15 μm), appears ideally suited to detect this phenomenon in vivo.2 We report on a patient treated with a drug-coated balloon (DCB) for recurrent in-stent restenosis (ISR) who at late follow-up developed NA as depicted by OCT and IVUS.

19 diciembre 2013

CIRCULATION. Coronary Heart Disease. Randomized Comparison of Xience V and Multi-Link Vision Coronary Stents in the Same Multivessel Patient With Chronic Kidney Disease (RENAL-DES) Study

Fabrizio Tomai, MD, FACC, FESC; Flavio Ribichini, MD; Leonardo De Luca, MD, FACC, PhD; Alessandro Petrolini, MD; Anna S. Ghini, MD, PhD; Luca Weltert, MD; Carmen Spaccarotella, MD; Igino Proietti, MD; Carlo Trani, MD; Francesco Nudi, MD; Michele Pighi, MD; Corrado Vassanelli, MD, FESC

Background: Percutaneous coronary interventions in patients with chronic kidney disease have shown suboptimal results. Drug-eluting stents (DES) might reduce the rate of target vessel revascularization in comparison with bare-metal stents (BMS) in patients with chronic kidney disease. However, given the multiple concomitant individual variables present in such patients, the comparison of neointimal growth after percutaneous coronary intervention is complex and difficult to assess.

03 enero 2014

CIRCULATION. Interventional Cardiology. ST-Elevation Myocardial Infarction Diagnosed After Hospital Admission

Ross F. Garberich, MS; Jay H. Traverse, MD; Michael T. Claussen, BS; Gabriel Rodriguez, BS; Anil K. Poulose, MD; Ivan J. Chavez, MD; Stephanie Rutten-Ramos, DVM, PhD; David A. Hildebrandt, RN; Timothy D. Henry, MD

Background: Treatment times for ST-elevation myocardial infarction (STEMI) patients presenting to percutaneous coronary intervention hospitals have improved dramatically over the past 10 years, particularly for patients using emergency medical services. Limited data exist regarding treatment times and outcomes for patients who develop STEMI after hospital admission.

26 diciembre 2013

CIRCULATION. Interventional Cardiology. Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation

Marina Urena, MD; John G. Webb, MD; Corrado Tamburino, MD; Antonio J. Muñoz-García, MD, PhD; Asim Cheema, MD; Antonio E. Dager, MD; Vicenç Serra, MD; Ignacio J. Amat-Santos, MD; Marco Barbanti, MD; Sebastiano Immè, MD; Juan H. Alonso Briales, MD; Luis Miguel Benitez, MD; Hatim Al Lawati, MD; Angela Maria Cucalon, MD; Bruno García del Blanco, MD; Javier López, MD, PhD; Eric Dumont, MD; Robert DeLarochellière, MD; Henrique B. Ribeiro, MD; Luis Nombela-Franco, MD; François Philippon, MD, FRCPC, FHRS; Josep Rodés-Cabau, MD

Background: Very few data exist on the clinical impact of permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation. The objective of this study was to assess the impact of PPI after transcatheter aortic valve implantation on late outcomes in a large cohort of patients.